1. Home
  2. AYTU vs ALCE Comparison

AYTU vs ALCE Comparison

Compare AYTU & ALCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AYTU
  • ALCE
  • Stock Information
  • Founded
  • AYTU N/A
  • ALCE 2019
  • Country
  • AYTU United States
  • ALCE United States
  • Employees
  • AYTU N/A
  • ALCE N/A
  • Industry
  • AYTU Biotechnology: Pharmaceutical Preparations
  • ALCE Power Generation
  • Sector
  • AYTU Health Care
  • ALCE Utilities
  • Exchange
  • AYTU Nasdaq
  • ALCE Nasdaq
  • Market Cap
  • AYTU 15.0M
  • ALCE 13.9M
  • IPO Year
  • AYTU N/A
  • ALCE N/A
  • Fundamental
  • Price
  • AYTU $2.32
  • ALCE $0.18
  • Analyst Decision
  • AYTU
  • ALCE
  • Analyst Count
  • AYTU 0
  • ALCE 0
  • Target Price
  • AYTU N/A
  • ALCE N/A
  • AVG Volume (30 Days)
  • AYTU 30.6K
  • ALCE 99.6K
  • Earning Date
  • AYTU 11-12-2024
  • ALCE 11-15-2024
  • Dividend Yield
  • AYTU N/A
  • ALCE N/A
  • EPS Growth
  • AYTU N/A
  • ALCE N/A
  • EPS
  • AYTU N/A
  • ALCE N/A
  • Revenue
  • AYTU $81,002,000.00
  • ALCE N/A
  • Revenue This Year
  • AYTU N/A
  • ALCE N/A
  • Revenue Next Year
  • AYTU N/A
  • ALCE N/A
  • P/E Ratio
  • AYTU N/A
  • ALCE N/A
  • Revenue Growth
  • AYTU N/A
  • ALCE N/A
  • 52 Week Low
  • AYTU $2.20
  • ALCE $0.14
  • 52 Week High
  • AYTU $3.50
  • ALCE $10.89
  • Technical
  • Relative Strength Index (RSI)
  • AYTU 44.21
  • ALCE 68.22
  • Support Level
  • AYTU $2.26
  • ALCE $0.14
  • Resistance Level
  • AYTU $2.47
  • ALCE $0.20
  • Average True Range (ATR)
  • AYTU 0.15
  • ALCE 0.02
  • MACD
  • AYTU -0.01
  • ALCE 0.01
  • Stochastic Oscillator
  • AYTU 13.56
  • ALCE 57.92

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.

About ALCE Alternus Clean Energy Inc.

Alternus Clean Energy Inc is an international independent clean energy producer. It develops, installs, owns and operates a diverse portfolio of utility-scale solar photovoltaic power stations (PV parks) in Europe and the USA as a long-term owner. The solar parks benefit from long-term government offtake contracts and/or Power Purchase Agreements (PPAs) with investment grade off-takers, plus energy sales to local power grids. It has approximately 8 operating parks, a total of 44 MWp in operation.

Share on Social Networks: